Company News - VC and PE investment business - Medical and health professional investment - Shenzhen Efung Investment Management Co. Ltd.

发布时间: 2026 - 07 - 21

A Century of Passive Immunity Rewritten — Today, by China.

July 21, 2026 — Zhuhai Trinomab Pharmaceutical Co., Ltd. (Stock Code: 688806.SH) officially debuted on the STAR Market (SSE Sci-Tech Innovation Board) at an IPO price of RMB 14.46 per share.This is far more than a Biotech's bell-ringing ceremony. It marks the first time in over a century that an original Chinese-developed antibody therapeutic has entered the capital markets to combat tetanus. It signals the closing chapter of an era — the old world of passive immunity, reliant on horse serum, burdened by allergy risks, and constrained by plasma supply, is turning a page. Notably, Trinomab ...

浏览次数：18

查看详情>>

发布时间: 2026 - 07 - 17

Efung News | China's Original "Intervention Without Implantation": Weiguang Medical's 355 nm Cold La

Recently, LightSaber, a single-use laser optical fiber catheter independently developed by Zhongke Rongguang, a subsidiary of Weiguang Medical, officially received approval for market launch from the National Medical Products Administration (NMPA) of China (Registration Certificate No.: 20263011418).The catheter is intended for use in combination with the previously approved FastErazer 355 nm cold laser atherectomy device (Registration Certificate No.: 20263011296) for the pretreatment of lower extremity atherosclerotic stenosis (including in-stent restenosis) and occlusive lesions, to facilit...

浏览次数：40

查看详情>>

发布时间: 2026 - 07 - 16

Efung Knowledge Planet | US$60 Billion in Outbound Deals in Q1: Top 10 Life Sciences Keywords for 20

China's life sciences industry has transformed into an innovation center of global significance, built upon accelerated regulatory pathways, strong policy support, and rapidly improving R&D efficiency across pharmaceuticals, medical devices, and biotechnology.Approximately 2,390 words | 5–6 min readFor a long time, China's innovative drug story was about the journey from "me-too" to "me-better." But halfway through 2026, the narrative has shifted—valuation is no longer driven by vision, but by hard metrics: pipeline data, deal values, and enrollment speed.KPMG&#...

浏览次数：17

查看详情>>

发布时间: 2026 - 07 - 15

A Monkey Costs Over 200,000 RMB – Are This Year's Monkeys Already Booked Out?

On July 15, the A-share market showed notable structural divergence, with the innovative drug sector leading gains across the board. Multiple sub-segments including CRO, weight-loss drugs, recombinant proteins, cellular immunotherapy, and generic innovation drugs all surged over 4%. On the same day, a piece of news about laboratory monkeys began circulating in the industry: the price of cynomolgus monkeys has exceeded 200,000 RMB per animal, and many monkey farms have told buyers that "this year's monkeys are already fully booked."These two seemingly unrelated pieces of informati...

浏览次数：14

查看详情>>